Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir.
Masquelier B, Assoumou KL, Descamps D, Bocket L, Cottalorda J, Ruffault A, Marcelin AG, Morand-Joubert L, Tamalet C, Charpentier C, Peytavin G, Antoun Z, Brun-Vézinet F, Costagliola D; ANRS Resistance Study Group. Masquelier B, et al. J Antimicrob Chemother. 2008 Jun;61(6):1362-8. doi: 10.1093/jac/dkn127. Epub 2008 Apr 4. J Antimicrob Chemother. 2008. PMID: 18390885
Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.
Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C, Ruffault A, Mohammed AS, Cottalorda J, Schmuck A, Calvez V, Dam E, Fleury H, Brun-Vézinet F; ANRS AC11 Resistance study group. French Agence Nationale de Recherches sur le SIDA. Masquelier B, et al. Antimicrob Agents Chemother. 2001 Jun;45(6):1836-42. doi: 10.1128/AAC.45.6.1836-1842.2001. Antimicrob Agents Chemother. 2001. PMID: 11353634 Free PMC article.
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.
Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V; ANRS AC11 Resistance Study Group. Marcelin AG, et al. Antimicrob Agents Chemother. 2010 Jan;54(1):72-7. doi: 10.1128/AAC.01051-09. Epub 2009 Nov 9. Antimicrob Agents Chemother. 2010. PMID: 19901096 Free PMC article.
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
Larrouy L, Chazallon C, Landman R, Capitant C, Peytavin G, Collin G, Charpentier C, Storto A, Pialoux G, Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D; ANRS 127 Study Group. Larrouy L, et al. Antimicrob Agents Chemother. 2010 Jul;54(7):2910-9. doi: 10.1128/AAC.00194-10. Epub 2010 May 3. Antimicrob Agents Chemother. 2010. PMID: 20439606 Free PMC article. Clinical Trial.
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group. Recordon-Pinson P, et al. Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7. Antimicrob Agents Chemother. 2010. PMID: 20530226 Free PMC article.
HIV-1 dynamics and coreceptor usage in Maraviroc-treated patients with ongoing replication.
Recordon-Pinson P, Raymond S, Bellecave P, Marcelin AG, Soulie C, Descamps D, Calvez V, Harrigan PR, Fleury H, Izopet J, Masquelier B; S AC11 Resistance Study Group. Recordon-Pinson P, et al. Antimicrob Agents Chemother. 2013 Feb;57(2):930-5. doi: 10.1128/AAC.02159-12. Epub 2012 Dec 3. Antimicrob Agents Chemother. 2013. PMID: 23208718 Free PMC article.
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group. Fourati S, et al. J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3. J Antimicrob Chemother. 2015. PMID: 25558077 Free article.
[Drugs active against retroviruses].
Brun-Vézinet F, Descamps D. Brun-Vézinet F, et al. Rev Prat. 1997 Mar 15;47(6):631-8. Rev Prat. 1997. PMID: 9183937 French.
358 results